Related Experiment Video

Updated: Jun 25, 2025

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

11.8K

IMPRESS-Norway: improving public cancer care by implementing precision medicine in Norway; inclusion rates and

Katarina Puco1, Gro Live Fagereng1, Sigmund Brabrand2

  • 1Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.

Acta Oncologica (Stockholm, Sweden)
|May 23, 2024
PubMed
Abstract

Insights

Precision cancer medicine in Norway shows promise, matching targeted therapies to tumor molecular profiles. The IMPRESS-Norway trial found a 40% disease control rate in evaluable patients, indicating improved outcomes for some with advanced cancer.

Area of Science:

  • Oncology
  • Genomics
  • Precision Medicine

Background:

  • Norway integrates comprehensive molecular tumor profiling into its public healthcare system.
  • A significant number of tumors exhibit potentially targetable molecular alterations.
  • Matching targeted treatments to genomic alterations can improve therapy outcomes.

Purpose of the Study:

  • To evaluate the effectiveness of precision cancer medicine in Norway through the IMPRESS-Norway trial.
  • To assess the disease control rate (DCR) in patients with advanced cancer treated with targeted therapies based on molecular profiling.

Main Methods:

  • The IMPRESS-Norway trial is a prospective, non-randomized study for advanced-stage cancer patients progressing on standard treatment.
  • Comprehensive next-generation sequencing (TruSight Oncology 500) is used for molecular profiling.
  • Patients receive targeted therapies matched to their tumor's molecular alterations, with 24 drugs currently available.

Main Results:

  • Between April 2021 and October 2023, 1,167 patients were screened, identifying actionable mutations for 358.
  • 186 patients initiated treatment, with 170 having at least 16 weeks of follow-up.
  • The disease control rate (DCR) was 40% (58/145) in evaluable patients and 34% (58/170) in all treated patients.

Conclusions:

  • Precision cancer medicine, guided by molecular tumor profiling, shows encouraging clinical effects in a subset of patients.
  • The IMPRESS-Norway trial demonstrates the feasibility and potential benefit of matching targeted therapies to genomic alterations within a public healthcare system.

More Related Videos

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.1K
Live Imaging of Drug Responses in the Tumor Microenvironment in Mouse Models of Breast Cancer08:26

Live Imaging of Drug Responses in the Tumor Microenvironment in Mouse Models of Breast Cancer

Published on: March 24, 2013

24.9K

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
343
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K